Clik here to view.
DiaCarta Announces the Termination of Business Combination Agreement with...
PLEASANTON, Calif. DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced the termination of its Business Combination Agreement with HH&L Acquisition Co. On June...
View ArticleClik here to view.
From blackboard to mortarboard: 23 scholars from 13 countries graduate from...
MEMPHIS, Tenn. ALSAC, the fundraising and awareness organization for St. Jude Children’s Research Hospital®, graduated the fourth cohort of the ALSAC Global Scholars Basic Fundraising Program on...
View ArticleClik here to view.
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the first psoriasis patient has...
View ArticleClik here to view.
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address...
CAMBRIDGE, Mass. VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today...
View ArticleClik here to view.
百奥赛图与Pheon Therapeutics达成授权协议
中国北京和英国伦敦 (美国商业资讯)– 百奥赛图（北京）医药科技股份有限公司（“百奥赛图”，股票代码02315.HK），一家专注于创新治疗性抗体发现的国际性生物技术公司，今天宣布与专注抗体药物偶联物（ADC）开发的Pheon...
View ArticleClik here to view.
Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics
BEIJING & LONDON Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces an...
View ArticleClik here to view.
INOVIQ and Promega Announce Global Joint Marketing Agreement for EXO-NET...
MELBOURNE, Australia & MADISON, Wis. INOVIQ Limited (ASX:IIQ) (INOVIQ), an innovative developer of exosome solutions and precision diagnostics, and Promega Corporation (Promega), a global leader...
View ArticleClik here to view.
バイオサイトジェン・ファーマシューティカルズ、Pheon Therapeuticsとライセンス契約を締結
北京 & ロンドン （ビジネスワイヤ） — 新たな抗体治療薬の発見に重点的に取り組む世界的バイオテクノロジー企業であるバイオサイトジェン・ファーマシューティカルズ（北京）（以下「バイオサイトジェン」、HKEX: 02315）は、Pheon Therapeutics...
View ArticleClik here to view.
BeiGene to Host Investor Research and Development Day in Person and via...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will host an investor...
View ArticleClik here to view.
BeiGene and DualityBio Announce Partnership to Advance Differentiated...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SUZHOU, China & SHANGHAI BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, and DualityBio, a...
View ArticleClik here to view.
進行固形腫瘍におけるGTAEXS617の「ELUCIDATE」第1/2相試験に最初の患者を登録
英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq: EXAI）は、進行固形腫瘍の治療に対して、精密設計されたCDK7阻害剤であるGTAEXS617...
View ArticleClik here to view.
评估GTAEXS617在晚期实体瘤中作用的1/2期“ELUCIDATE”试验招募了首位患者
英国牛津 (美国商业资讯)– Exscientia plc (Nasdaq:...
View ArticleClik here to view.
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
MELBOURNE, Australia Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND)...
HANGZHOU, China Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ...
View ArticleClik here to view.
エクセンシア、卵巣がんのプロスペクティブ観察研究を開始
英オックスフォード & オーストリア、ウィーン （ビジネスワイヤ） — エクセンシア（Nasdaq: EXAI）は、自社の精密医療プラットフォームを使用して、原発巣の腫瘍細胞試料におけるex...
View ArticleClik here to view.
Clik here to view.
VANFLYTA® First FLT3 Inhibitor Approved in the U.S. Specifically for Patients...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) today announced that VANFLYTA® (quizartinib) has been approved by the U.S. Food and Drug Administration (FDA) in combination with standard...
View ArticleClik here to view.
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Committee for Medicinal Products...
View ArticleClik here to view.
CDISC Selects Myota to Protect IP Against Ransomware Attacks
PHILADELPHIA & AUSTIN, Texas Myota, a prominent data protection platform provider, is excited to announce its newest customer, CDISC, a global standards development organization that serves the...
View ArticleClik here to view.
InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has received...
View Article